Skip to main content
. 2020 Feb 15;201(4):430–437. doi: 10.1164/rccm.201906-1206OC

Figure 1.

Figure 1.

(A and B) FEV1% predicted (FEV1pp) over 3 years (using all data and, separately, only yearly maximum) after incident chronic azithromycin (AZM) versus control among those without Pseudomonas aeruginosa (A) and those with P. aeruginosa (B). Estimates for all data were derived from the model allowing individual trends per year.